Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

Joanna M Zakrzewska, Joanne Palmer, Dominik A Ettlin, Mark Obermann, Gerard M P Giblin, Valerie Morisset, Simon Tate, Kevin Gunn, Joanna M Zakrzewska, Joanne Palmer, Dominik A Ettlin, Mark Obermann, Gerard M P Giblin, Valerie Morisset, Simon Tate, Kevin Gunn

Abstract

Background: Trigeminal neuralgia (TN) is a rare severe unilateral facial pain condition. Current guidelines in trigeminal neuralgia management recommend sodium channel blockers--carbamazepine or oxcarbazepine--as the first-line treatment. However, the currently available drugs are often associated with poor tolerability resulting in sub-optimal pain control. CNV1014802 is a novel sodium channel blocker that is being assessed in the treatment of trigeminal neuralgia. Due to the severity of the condition, it is not ethical to conduct a traditional placebo-controlled randomized controlled trial. It is also difficult to use an active control such as carbamazepine, the current gold standard, because of its complex pharmacology and potential for drug interactions.

Methods/design: The trial uses a randomized withdrawal design to assess efficacy in this rare condition. There is a 21-day open-label phase followed by a randomized 28-day placebo-controlled phase for responders. Thirty patients will be randomized. The primary outcome measure will be pain relief, but secondary measures of quality of life will be of significant importance given the effect of this condition on activities of daily living. Safety and adverse event endpoints are described.

Discussion: There have been very few well-controlled, randomized, placebo-controlled studies in trigeminal neuralgia, and the majority of drugs have had other primary uses. Due to the severity of the pain, minimizing the time a patient is administered placebo was a key factor in designing this study. This study will not only provide data on the efficacy of CNV1014802 in trigeminal neuralgia, but will also provide information on the effectiveness and acceptability of a novel trial design in trigeminal neuralgia.

Trial registration: Trial number NCT01540630.

Figures

Figure 1
Figure 1
Design of the study.
Figure 2
Figure 2
Pain diary completed by the patient on a daily basis.

References

    1. Obermann M, Yoon MS, Dommes P, Kuznetsova J, Maschke M, Weimar C, Limmroth V, Diener HC, Katsarava Z. Prevalence of trigeminal autonomic symptoms in migraine: a population-based study. Cephalalgia. 2007;27(6):504–509. doi: 10.1111/j.1468-2982.2007.01316.x.
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945–1984. Neuroepidemiology. 1991;10(5–6):276–281.
    1. van Kleef M, van Genderen WE, Narouze S, Nurmikko TJ, van Zundert J, Geurts JW, Mekhail N. 1. Trigeminal neuralgia. Pain Pract. 2009;9(4):252–259. doi: 10.1111/j.1533-2500.2009.00298.x.
    1. Koopman JS, Dieleman JP, Huygen FJ, De Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147(1–3):122–127.
    1. IHS. IHS Classification ICHD-111 Beta version. 2013. pp. 629–808.
    1. Obermann M, Yoon MS, Ese D, Maschke M, Kaube H, Diener HC, Katsarava Z. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology. 2007;69(9):835–841. doi: 10.1212/01.wnl.0000269670.30045.6b.
    1. Prasad S, Galetta S. Trigeminal neuralgia: historical notes and current concepts. Neurologist. 2009;15(2):87–94. doi: 10.1097/NRL.0b013e3181775ac3.
    1. Zakrzewska JM. Diagnosis and differential diagnosis of trigeminal neuralgia. Clin J Pain. 2002;18(1):14–21. doi: 10.1097/00002508-200201000-00003.
    1. Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, Wang LJ. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443–450. doi: 10.1177/0333102412441721.
    1. Rothman KJ, Monson RR. Survival in trigeminal neuralgia. J Chronic Dis. 1973;26(5):303–309. doi: 10.1016/0021-9681(73)90033-7.
    1. Taylor JC, Brauer S, Espir MLE. Long-term treatment of trigeminal neuralgia. Postgrad Med J. 1981;57:16–18. doi: 10.1136/pgmj.57.663.16.
    1. Beydoun A, Schmidt D, D’Souza D. Oxcarbazepine versus carbamazepine in trigeminal neuralgia : a meta-anlaysis of three double blind comparative trials. [abstract] Neurol. 2002;58:p02.083.
    1. Anonymous. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
    1. Anon. The international classification of headache disorders, 3rd edition (beta version) Cephalalgia. 2013;33(9):629–808.
    1. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013–1028. doi: 10.1111/j.1468-1331.2008.02185.x.
    1. Obermann M, Yoon MS, Sensen K, Maschke M, Diener HC, Katsarava Z. Efficacy of pregabalin in the treatment of trigeminal neuralgia. Cephalalgia. 2008;28(2):174–181.
    1. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011;1:CD005451.
    1. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68(1):63–67. doi: 10.1016/j.eplepsyres.2005.09.023.
    1. Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, Motamedi GK, Evans BM, Baum C. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology. 2007;69(22):2076–2084. doi: 10.1212/01.wnl.0000281104.55418.60.
    1. Motamedi GK, Meador KJ. Antiepileptic drugs and memory. Epilepsy Behav. 2004;5(4):435–439. doi: 10.1016/j.yebeh.2004.03.006.
    1. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol. 2011;93(3):385–404. doi: 10.1016/j.pneurobio.2011.01.002.
    1. Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the NaV1.7 sodium channel. Ann N Y Acad Sci. 2010;1184:196–207. doi: 10.1111/j.1749-6632.2009.05110.x.
    1. Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, Merkies IS. Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 2012;71(1):26–39. doi: 10.1002/ana.22485.
    1. Pietrobon D. Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine. J Physiol. 2010;588(Pt 11):1871–1878.
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ. 2013;346:f2690. doi: 10.1136/bmj.f2690.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Jorns TP, Zakrzewska JM. Evidence-based approach to the medical management of trigeminal neuralgia. Br J Neurosurg. 2007;21(3):253–261. doi: 10.1080/02688690701219175.
    1. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. 2011;2(2):CD006044.
    1. Yang M, Zhou M, He L, Chen N, Zakrzewska JM. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev. 2011;1:CD004029.
    1. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135(3):217–220. doi: 10.1016/j.pain.2008.01.014.
    1. Quessy SN. Two-stage enriched enrolment pain trials: a brief review of designs and opportunities for broader application. Pain. 2010;148(1):8–13. doi: 10.1016/j.pain.2009.10.029.
    1. Jorns TP, Johnston A, Zakrzewska JM. Pilot study to evaluate the efficacy and tolerability of leviteracetam (keppra) in the treatment of patients with trigemional neuralgia. Eur J Neurol. 2009;16:740–744. doi: 10.1111/j.1468-1331.2009.02585.x.
    1. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.
    1. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73(2):223–230. doi: 10.1016/S0304-3959(97)00104-8.
    1. Lee JY, Chen HI, Urban C, Hojat A, Church E, Xie SX, Farrar JT. Development of and psychometric testing for the brief pain inventory-facial in patients with facial pain syndromes. J Neurosurg. 2010;113(3):516–523. doi: 10.3171/2010.1.JNS09669.
    1. Baker GA, Frances P, Middleton E. Initial development, reliability, and validity of a patient-based adverse event scale. Epilepsia. 1994;35(suppl 7):80.
    1. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23–27. doi: 10.1212/WNL.62.1.23.
    1. Hays RD, Sherbourne CD, Mazel RM. User’s manual for medical outcomes study (MOS) Core Measures of Health-Related Quality of Life. Santa Monica; 1995. (Rand Corporation MR-162-RC).
    1. Stewart AL, Ware JE, Sherbourne CD. In: Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Stewart AL, Ware JE, editor. Durham NC: Duke University; 1992. Psychological distress/well-being and cognitive functioning measures; pp. 102–142.
    1. Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72(14):1223–1229. doi: 10.1212/01.wnl.0000345667.45642.61.
    1. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285(15):1992–1995. doi: 10.1001/jama.285.15.1992.
    1. Gilron I, Booher SL, Rowan JS, Max MB. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol. 2001;24(2):109–112. doi: 10.1097/00002826-200103000-00009.
    1. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2(1):e000496.
    1. Ellis PE, Bradley RL, Sandy JR, Deacon SA, Griffiths HS, Atack NE, Moore MB, House KA, Wenger NA, Worth V, Ireland AJ. Do I have enough time? The impact of recruiting patients to a randomised controlled trial at recruiting centres. Br Dent J. 2012;213(9):467–470. doi: 10.1038/sj.bdj.2012.986.
    1. Lechin F, van der Dijs B, Lechin ME, Amat J, Lechin AE, Cabrera A, Gomez F, Acosta E, Arocha L, Villa S, Jienez V. Pimozide therapy for trigeminal neuralgia. Arch Neurol. 1989;46:960–963. doi: 10.1001/archneur.1989.00520450030015.
    1. Lindstrom P, Lindblom V. The analgesic effect of tocainide in trigeminal neuralgia. Pain. 1987;28:45–50. doi: 10.1016/0304-3959(87)91058-X.
    1. Vilming ST, Lyberg T, Latase X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia. 1986;6:181–182. doi: 10.1046/j.1468-2982.1986.0603181.x.
    1. Shaikh S, Yaacob HB, Abd Rahman RB. Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. J Chin Med Assoc. 2011;74(6):243–249. doi: 10.1016/j.jcma.2011.04.002.
    1. Lemos L, Flores S, Oliveira P, Almeida A. Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. Clin J Pain. 2008;24(1):64–75. doi: 10.1097/AJP.0b013e318158011a.
    1. Liebel JT, Menger N, Langohr H. Oxcarbazepine in der Behandlung der Trigeminusneuralgie. Nervenheilkd. 2001;20:461–465.
    1. Godlee F. Publishing study protocols: making them visible will improve registration, reporting and recruitment. BMC News and Views. 2001;2:4.
    1. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA. 2009;302(9):977–984. doi: 10.1001/jama.2009.1242.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅